Moreover, development of personalized medicine of lung adenocarcinoma, the discovery of various genetic alterations that promote cancer growth and survival, such as EGFR mutations and EML4-ALK rearrangements, have revolutionized treatment paradigms for patients (Kwak et al. 2010). The gene discussed is EML4; the disease is lung adenocarcinoma.